Dextroamphetamine for ADHD and Narcolepsy
Dextroamphetamine is an effective FDA-approved treatment for both ADHD (ages 3-16 years) and narcolepsy (ages 6+), but carries significant risks including high abuse potential (Schedule II), cardiovascular effects, and growth suppression, requiring careful dose titration and monitoring.
FDA-Approved Indications
Dextroamphetamine is indicated for:
- ADHD: Ages 3-16 years as part of comprehensive treatment including behavioral interventions 1
- Narcolepsy: Ages 6 years and older 1
Dosing Guidelines
For ADHD 1
- Ages 3-5 years: Start 2.5 mg daily; increase by 2.5 mg weekly until optimal response (rarely exceeds 40 mg/day total)
- Ages 6+ years: Start 5 mg once or twice daily; increase by 5 mg weekly until optimal response (rarely exceeds 40 mg/day total)
- Not recommended under age 3
For Narcolepsy 1
- Ages 6-12 years: Start 5 mg daily; increase by 5 mg weekly until optimal response
- Ages 12+ years: Start 10 mg daily; increase by 10 mg weekly until optimal response
- Usual effective range: 5-60 mg/day in divided doses
Dosing Strategy
- Give first dose upon awakening
- Additional doses (1-2) at 4-6 hour intervals 1
- Avoid late evening doses due to insomnia 1
- Flexible titration to higher doses improves both efficacy and acceptability compared to fixed dosing, as practitioners can adjust based on symptom control and tolerability 2
Critical Contraindications and Warnings
Black Box Warning 3
High potential for abuse and prolonged administration may lead to dependence. This is an FDA Schedule II controlled substance.
Cardiovascular Risks
- Increases systolic BP by 1.93 mmHg and diastolic BP by 1.84 mmHg 4
- Increases heart rate by 3.71 beats per minute 4
- These effects persist with chronic use (≥8 weeks) 4
- Before initiating treatment, assess for cardiac disease: obtain careful personal and family history of sudden death or ventricular arrhythmia, perform physical exam 1
Pregnancy and Lactation
- May cause fetal harm based on animal data; human data insufficient 3
- However, recent case series suggests therapeutic use for narcolepsy may not be associated with adverse obstetric/neonatal outcomes when individualized 5
- Balance maternal functional needs against potential risks
Tics and Tourette's
- Assess family history and clinically evaluate for motor/verbal tics or Tourette's syndrome before treatment 1
Common Adverse Effects
Most Frequent 3
- Sweatiness
- Edginess/irritability
- Loss of appetite
- Weight changes (both gain and loss reported)
Serious Adverse Effects
- Growth suppression: Height and weight delays in first 1-2 years of treatment in children, with return to expected measurements after 2-3 years 6
- Stimulant-induced psychosis: Rare but documented in case reports 7
- Hyperthermia, seizures, tachyarrhythmias in overdose 8
- Withdrawals due to adverse effects 2.69 times higher than placebo 4
Special Population Considerations
Preschool Children (Ages 4-5)
Methylphenidate is preferred over dextroamphetamine for preschool-aged children despite amphetamine having FDA approval for under age 6 (issued under less stringent criteria). Evidence for dextroamphetamine in this age group is inadequate 6.
Narcolepsy Treatment Position
The American Academy of Sleep Medicine conditionally suggests dextroamphetamine for narcolepsy in adults (very low quality evidence), demonstrating clinically significant improvements in excessive daytime sleepiness and cataplexy 3. It is one of four FDA-approved medications for excessive daytime sleepiness in narcolepsy 9.
Monitoring Requirements
- Interrupt drug administration occasionally to determine if behavioral symptoms recur and continued therapy is necessary 1
- Monitor blood pressure, heart rate, growth parameters (height/weight in children)
- Assess for signs of abuse, dependence, or diversion
- Watch for emergence of psychotic symptoms or mood changes
Clinical Pitfalls to Avoid
- Underdosing: Stimulants are often underdosed in practice 2. Titrate flexibly to maximize symptom control within tolerated dose range.
- Fixed dosing without adjustment: Flexible titration based on response and tolerability provides better outcomes than rigid fixed dosing 2.
- Late evening administration: Causes insomnia; avoid 1.
- Inadequate cardiovascular screening: Always assess cardiac history before initiating 1.
- Using as first-line in preschoolers: Methylphenidate has stronger evidence in ages 4-5 6.